




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

FIG. 6A

Cell Proliferation Multiple Myeloma (RPMI8226)




FIG. 6B

Cell Proliferation Multiple Myeloma (H929)




FIG. 6C

Cell Proliferation Burkitt Lymphoma (GA10)




FIG. 6D

Cell Proliferation Follicular Lymphoma (DoHH-2)




FIG. 7A




FIG. 7B

Dose (mg/kg)	Time point (h)	Drug levels in plasma (ng/ml)	% Inhibition of ATF4
50	2	32603	88
50	6	28141	91
50	10	27880	87
25	2	11443	79
25	6	24759	93
25	10	2210	57




FIG. 8

FIG. 9A




FIG. 9B




FIG. 10A





FIG. 10B





FIG. 10C





FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 14A




FIG. 14B

Dose (mg/kg)	Time point (hr)	Compound 2 plasma level (ng/ml)
10	2	12041
10	6	4797
10	10	2759
5	2	9497
5	6	842
5	10	470
1	2	812
1	6	362
1	10	199

FIG. 15A




FIG. 15B

